GBLX Stock Overview
GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
GB Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0064 |
| 52 Week High | US$0.02 |
| 52 Week Low | US$0.005 |
| Beta | 0.35 |
| 1 Month Change | 17.18% |
| 3 Month Change | 17.18% |
| 1 Year Change | -62.53% |
| 3 Year Change | -87.61% |
| 5 Year Change | -96.13% |
| Change since IPO | -99.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| GBLX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.8% | -2.2% | -3.7% |
| 1Y | -62.5% | 11.6% | 20.5% |
Return vs Industry: GBLX underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: GBLX underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| GBLX volatility | |
|---|---|
| GBLX Average Weekly Movement | 17.5% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GBLX has not had significant price volatility in the past 3 months.
Volatility Over Time: GBLX's weekly volatility has decreased from 23% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 3 | John Poss | www.gbsciences.com |
GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson’s disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs.
GB Sciences, Inc. Fundamentals Summary
| GBLX fundamental statistics | |
|---|---|
| Market cap | US$2.62m |
| Earnings (TTM) | -US$4.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs GBLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBLX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.03m |
| Earnings | -US$4.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0099 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -31.2% |
How did GBLX perform over the long term?
See historical performance and comparison